Acadia Pharmaceuticals at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

Acadia Pharmaceuticals takes part in 1 session at CTAD 2026 in Boston. Its program looks at the biomarker profile of patients who meet clinical criteria for Alzheimer's disease psychosis, the condition its neuropsychiatric research targets.

OrganizationCTAD 2026 Attendance
Acadia Pharmaceuticals
San Diego, California
◇Silver Sponsor
acadia.com
BiotechSilver Sponsor
Develops and markets neuroscience medicines, including pimavanserin (Nuplazid) for Parkinson's disease psychosis, and studies treatments for neuropsychiatric symptoms.
Poster
Wed Nov 18
7:15am–5:30pm

Explore the full CTAD 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Boston. Leave your work email and we’ll be in touch.

Privacy

Download the full CTAD 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Acadia Pharmaceuticals

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction